Merck & Co., Inc. $MRK Shares Newly Bought by White Pine Capital LLC

White Pine Capital LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,086 shares of the company’s stock, valued at approximately $4,953,000. Merck & Co., Inc. comprises about 1.2% of White Pine Capital LLC’s investment portfolio, making the stock its 15th largest position.

Other hedge funds also recently made changes to their positions in the company. Thoroughbred Financial Services LLC lifted its stake in Merck & Co., Inc. by 1.1% during the 3rd quarter. Thoroughbred Financial Services LLC now owns 17,828 shares of the company’s stock valued at $2,590,000 after acquiring an additional 193 shares during the period. Bessemer Group Inc. lifted its position in Merck & Co., Inc. by 128.4% during the third quarter. Bessemer Group Inc. now owns 2,468,137 shares of the company’s stock valued at $358,647,000 after purchasing an additional 1,387,722 shares in the last quarter. SGL Investment Advisors Inc. grew its stake in shares of Merck & Co., Inc. by 5.4% during the 3rd quarter. SGL Investment Advisors Inc. now owns 8,642 shares of the company’s stock valued at $1,268,000 after acquiring an additional 445 shares during the period. Pettee Investors Inc. increased its stake in shares of Merck & Co., Inc. by 6.7% in the third quarter. Pettee Investors Inc. now owns 10,098 shares of the company’s stock worth $1,467,000 after purchasing an additional 633 shares in the last quarter. Finally, FDx Advisors Inc. raised its holdings in Merck & Co., Inc. by 11.5% during the third quarter. FDx Advisors Inc. now owns 3,384 shares of the company’s stock valued at $492,000 after acquiring an additional 348 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $147.74 on Monday. Merck & Co., Inc. has a 52 week low of $91.49 and a 52 week high of $156.92. The stock has a market capitalization of $364.21 billion, a P/E ratio of 152.31, a PEG ratio of 6.77 and a beta of 0.13. The firm has a fifty day simple moving average of $146.16 and a two-hundred day simple moving average of $128.61. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. The firm had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.58 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Latest Merck & Co., Inc. News

Investors following MRK have been watching these news items:

  • Positive Sentiment: The EMA’s CHMP recommended expanding ENFLONSIA’s use to help prevent severe RSV lower respiratory tract disease in vulnerable children up to 24 months old, including through their second RSV season. The broader eligible population could support the medicine’s commercial opportunity in Europe. Merck ENFLONSIA CHMP recommendation
  • Positive Sentiment: The CHMP also recommended WELIREG plus lenvatinib for adults with advanced clear-cell renal cell carcinoma after anti-PD-1/PD-L1 treatment. This would extend WELIREG into another treatment setting and expand Merck’s oncology portfolio in Europe. Merck WELIREG CHMP recommendation
  • Neutral Sentiment: Both decisions are CHMP recommendations; European Commission approval is still needed. Any financial contribution will also depend on launch timing, uptake and competition.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MRK shares. Guggenheim raised their target price on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Barclays increased their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the company an “overweight” rating in a report on Monday, October 26th. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, August 20th. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a research report on Wednesday, August 12th. Finally, Morgan Stanley dropped their price target on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $155.74.

Check Out Our Latest Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.